181 related articles for article (PubMed ID: 12672252)
1. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.
López-Rodríguez ML; Viso A; Ortega-Gutiérrez S; Fowler CJ; Tiger G; de Lago E; Fernández-Ruiz J; Ramos JA
J Med Chem; 2003 Apr; 46(8):1512-22. PubMed ID: 12672252
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
López-Rodríguez ML; Viso A; Ortega-Gutiérrez S; Lastres-Becker I; González S; Fernández-Ruiz J; Ramos JA
J Med Chem; 2001 Dec; 44(26):4505-8. PubMed ID: 11741470
[TBL] [Abstract][Full Text] [Related]
3. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
Vandevoorde S; Jonsson KO; Fowler CJ; Lambert DM
J Med Chem; 2003 Apr; 46(8):1440-8. PubMed ID: 12672243
[TBL] [Abstract][Full Text] [Related]
4. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.
Bisogno T; Melck D; Bobrov MYu ; Gretskaya NM; Bezuglov VV; De Petrocellis L; Di Marzo V
Biochem J; 2000 Nov; 351 Pt 3(Pt 3):817-24. PubMed ID: 11042139
[TBL] [Abstract][Full Text] [Related]
5. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
Reggio PH; Traore H
Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
[TBL] [Abstract][Full Text] [Related]
6. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide.
Jonsson KO; Vandevoorde S; Lambert DM; Tiger G; Fowler CJ
Br J Pharmacol; 2001 Aug; 133(8):1263-75. PubMed ID: 11498512
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
Deutsch DG; Lin S; Hill WA; Morse KL; Salehani D; Arreaza G; Omeir RL; Makriyannis A
Biochem Biophys Res Commun; 1997 Feb; 231(1):217-21. PubMed ID: 9070252
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors.
López-Rodríguez ML; Viso A; Ortega-Gutiérrez S; Fowler CJ; Tiger G; de Lago E; Fernández-Ruiz J; Ramos JA
Eur J Med Chem; 2003 Apr; 38(4):403-12. PubMed ID: 12750028
[TBL] [Abstract][Full Text] [Related]
11. Novel selective and metabolically stable inhibitors of anandamide cellular uptake.
Ortar G; Ligresti A; De Petrocellis L; Morera E; Di Marzo V
Biochem Pharmacol; 2003 May; 65(9):1473-81. PubMed ID: 12732359
[TBL] [Abstract][Full Text] [Related]
12. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
13. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.
Ruiz-Llorente L; Ortega-Gutiérrez S; Viso A; Sánchez MG; Sánchez AM; Fernández C; Ramos JA; Hillard C; Lasunción MA; López-Rodríguez ML; Díaz-Laviada I
Br J Pharmacol; 2004 Feb; 141(3):457-67. PubMed ID: 14718261
[TBL] [Abstract][Full Text] [Related]
14. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
[TBL] [Abstract][Full Text] [Related]
15. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin.
Fowler CJ; Tiger G; López-Rodríguez ML; Viso A; Ortega-Gutiérrez S; Ramos JA
J Enzyme Inhib Med Chem; 2003 Jun; 18(3):225-31. PubMed ID: 14506913
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
Giuffrida A; Beltramo M; Piomelli D
J Pharmacol Exp Ther; 2001 Jul; 298(1):7-14. PubMed ID: 11408519
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide.
Glaser ST; Deutsch DG; Studholme KM; Zimov S; Yazulla S
Vis Neurosci; 2005; 22(6):693-705. PubMed ID: 16469181
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
Brizzi A; Brizzi V; Cascio MG; Bisogno T; Sirianni R; Di Marzo V
J Med Chem; 2005 Nov; 48(23):7343-50. PubMed ID: 16279794
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
